Successful treatment of postinfectious bronchiolitis obliterans with gamma globulin in a tertiary center: 10 years of experience

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Asli Imran
dc.contributor.authorGul, Yahya
dc.contributor.authorKapakli, Hasan
dc.contributor.authorUnal, Gokcen
dc.contributor.authorCaglar, Hanife Tugce
dc.contributor.authorErcan, Fatih
dc.contributor.authorReisli, Ismail
dc.date.accessioned2024-02-23T13:03:31Z
dc.date.available2024-02-23T13:03:31Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractIntroductionBronchiolitis obliterans is characterized by partial or total occlusion of the bronchioles due to inflammation and fibrosis, and the most common form is postinfectious bronchiolitis obliterans (PIBO). This study aimed to retrospectively present our intravenous immunoglobulin (IVIG) treatment experience in PIBO patients with a clinically severe course despite receiving commonly used treatment protocols. Materials and MethodsThe study included patients aged 0-18 with subtle immunological abnormalities who were followed up in our center for PIBO between 2010 and 2021. Clinical evaluation, body mass index (BMI), computerized tomography (CT) image scoring, and immunological parameters were recorded before and after IVIG treatment. ResultsOf the 11 patients included in the study, 90% were male, the mean age at diagnosis was 27.1 months (range: 5-68 months) and the mean current age was 81.4 months (range: 15-188 months). The number of hospital visits due to infection and the frequency of hospitalizations decreased markedly in the patients who underwent IVIG therapy. Oxygen therapy was discontinued in all patients, and improvements in radiological severity scores were observed. BMI z-scores improved over the baseline values after IVIG therapy. ConclusionCorticosteroids are considered the best first-line treatment to control inflammation in PIBO. In our study group, PIBO patients showed favorable clinical and radiological responses to regular IVIG treatment, possibly due to minor immune deficiency secondary to steroids or as a result of undetected adaptive and innate immune defects involved in the etiology of severe PIBO.en_US
dc.identifier.doi10.1002/ppul.26577
dc.identifier.endpage2776en_US
dc.identifier.issn8755-6863
dc.identifier.issn1099-0496
dc.identifier.issue10en_US
dc.identifier.pmid37469295en_US
dc.identifier.scopus2-s2.0-85165489222en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2769en_US
dc.identifier.urihttps://doi.org/10.1002/ppul.26577
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10656
dc.identifier.volume58en_US
dc.identifier.wosWOS:001029388700001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Pulmonologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBronchiolitis Obliteransen_US
dc.subjectIntravenous Immunoglobulinen_US
dc.subjectPostinfectious Bronchiolitis Obliteransen_US
dc.titleSuccessful treatment of postinfectious bronchiolitis obliterans with gamma globulin in a tertiary center: 10 years of experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu